Literature DB >> 24068106

Estrogen responsiveness of the TFIID subunit TAF4B in the normal mouse ovary and in ovarian tumors.

Jennifer R Wardell1, Kendra M Hodgkinson, April K Binder, Kimberly A Seymour, Kenneth S Korach, Barbara C Vanderhyden, Richard N Freiman.   

Abstract

Estrogen signaling in the ovary is a fundamental component of normal ovarian function, and evidence also indicates that excessive estrogen is a risk factor for ovarian cancer. We have previously demonstrated that the gonadally enriched TFIID subunit TAF4B, a paralog of the general transcription factor TAF4A, is required for fertility in mice and for the proliferation of ovarian granulosa cells following hormonal stimulation. However, the relationship between TAF4B and estrogen signaling in the normal ovary or during ovarian tumor initiation and progression has yet to be defined. Herein, we show that Taf4b mRNA and TAF4B protein, but not Taf4a mRNA or TAF4A protein, are increased in whole ovaries and granulosa cells of the ovary after exposure to 17beta-estradiol or the synthetic estrogen diethylstilbestrol and that this response occurs within hours after stimulation. Furthermore, this increase occurs via nuclear estrogen receptors both in vivo and in a mouse granulosa cancer cell line, NT-1. We observe a significant increase in Taf4b mRNA in estrogen-supplemented mouse ovarian tumors, which correlates with diminished survival of these mice. These data highlight the novel response of the general transcription factor TAF4B to estrogen in the normal ovary and during ovarian tumor progression in the mouse, suggesting its potential role in regulating actions downstream of estrogen stimulation.

Entities:  

Keywords:  TAF4B; estradiol/estradiol receptor; ovarian cancer; ovary; premature ovarian failure

Mesh:

Substances:

Year:  2013        PMID: 24068106      PMCID: PMC4076380          DOI: 10.1095/biolreprod.113.111336

Source DB:  PubMed          Journal:  Biol Reprod        ISSN: 0006-3363            Impact factor:   4.285


  45 in total

1.  Requirement of tissue-selective TBP-associated factor TAFII105 in ovarian development.

Authors:  R N Freiman; S R Albright; S Zheng; W C Sha; R E Hammer; R Tjian
Journal:  Science       Date:  2001-09-14       Impact factor: 47.728

2.  Sp1 binding sites and an estrogen response element half-site are involved in regulation of the human progesterone receptor A promoter.

Authors:  L N Petz; A M Nardulli
Journal:  Mol Endocrinol       Date:  2000-07

3.  Reproductive hormone-induced, STAT3-mediated interleukin 6 action in normal and malignant human ovarian surface epithelial cells.

Authors:  Viqar Syed; Gregory Ulinski; Samuel C Mok; Shuk-Mei Ho
Journal:  J Natl Cancer Inst       Date:  2002-04-17       Impact factor: 13.506

4.  Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial.

Authors:  Garnet L Anderson; Howard L Judd; Andrew M Kaunitz; David H Barad; Shirley A A Beresford; Mary Pettinger; James Liu; S Gene McNeeley; Ana Maria Lopez
Journal:  JAMA       Date:  2003-10-01       Impact factor: 56.272

5.  The absence of ER-β results in altered gene expression in ovarian granulosa cells isolated from in vivo preovulatory follicles.

Authors:  April K Binder; Karina F Rodriguez; Katherine J Hamilton; Patricia S Stockton; Casey E Reed; Kenneth S Korach
Journal:  Endocrinology       Date:  2013-04-11       Impact factor: 4.736

6.  A comparison of the estrogenic potencies of estradiol, ethynylestradiol, diethylstilbestrol, nonylphenol and methoxychlor in vivo and in vitro.

Authors:  Leroy C Folmar; Michael J Hemmer; Nancy D Denslow; Kevin Kroll; Jian Chen; Ann Cheek; Harold Richman; Hillary Meredith; E Gordon Grau
Journal:  Aquat Toxicol       Date:  2002-10-02       Impact factor: 4.964

7.  Menopausal hormone replacement therapy and risk of ovarian cancer.

Authors:  James V Lacey; Pamela J Mink; Jay H Lubin; Mark E Sherman; Rebecca Troisi; Patricia Hartge; Arthur Schatzkin; Catherine Schairer
Journal:  JAMA       Date:  2002-07-17       Impact factor: 56.272

8.  Risk factors for invasive epithelial ovarian cancer: results from a Swedish case-control study.

Authors:  Tomas Riman; Paul W Dickman; Staffan Nilsson; Nestor Correia; Hans Nordlinder; Cecilia M Magnusson; Ingemar R Persson
Journal:  Am J Epidemiol       Date:  2002-08-15       Impact factor: 4.897

9.  A study of plasma progesterone, oestradiol-17beta, prolactin and LH levels, and of the luteal phase appearance of the ovaries in patients with endometriosis and infertility.

Authors:  I A Brosens; P R Koninckx; P A Corveleyn
Journal:  Br J Obstet Gynaecol       Date:  1978-04

10.  Transcriptional profiling of estrogen-regulated gene expression via estrogen receptor (ER) alpha or ERbeta in human osteosarcoma cells: distinct and common target genes for these receptors.

Authors:  Fabio Stossi; Daniel H Barnett; Jonna Frasor; Barry Komm; C Richard Lyttle; Benita S Katzenellenbogen
Journal:  Endocrinology       Date:  2004-03-19       Impact factor: 4.736

View more
  5 in total

Review 1.  Estrogen signaling crosstalk: Implications for endocrine resistance in ovarian cancer.

Authors:  Jennifer R Ribeiro; Richard N Freiman
Journal:  J Steroid Biochem Mol Biol       Date:  2014-02-22       Impact factor: 4.292

Review 2.  Mechanisms controlling germline cyst breakdown and primordial follicle formation.

Authors:  Chao Wang; Bo Zhou; Guoliang Xia
Journal:  Cell Mol Life Sci       Date:  2017-02-14       Impact factor: 9.261

3.  Soy promotes juvenile granulosa cell tumor development in mice and in the human granulosa cell tumor-derived COV434 cell line.

Authors:  Nadéra Mansouri-Attia; Rebecca James; Alysse Ligon; Xiaohui Li; Stephanie A Pangas
Journal:  Biol Reprod       Date:  2014-08-27       Impact factor: 4.285

4.  Notch3 overexpression promotes anoikis resistance in epithelial ovarian cancer via upregulation of COL4A2.

Authors:  Caitlin W Brown; Alexander S Brodsky; Richard N Freiman
Journal:  Mol Cancer Res       Date:  2014-08-28       Impact factor: 5.852

Review 5.  Targeting TBP-Associated Factors in Ovarian Cancer.

Authors:  Jennifer R Ribeiro; Lindsay A Lovasco; Barbara C Vanderhyden; Richard N Freiman
Journal:  Front Oncol       Date:  2014-03-11       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.